BioCryst Provides Tremendous Option Value
The introduction of ORLADEYO has been a runaway success, and this is likely to continue with new payors and subscribers getting on board and international sales just around the corner. […]
What to buy? Gamble on biotech stocks
The regulatory approval process for new drugs is Byzantine, lengthy, and unpredictable. Single stocks are, for outsiders at least (even insiders can be surprised), almost pure bets. But one can […]